{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:53:21Z","timestamp":1793987601665,"version":"4.8.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>IPOPI held its first Global Multi-Stakeholders\u2019 Summit on 23-24 June 2022 in Cascais, Portugal. This IPOPI initiative was designed to set the stage for a stimulating forward-thinking meeting and brainstorming discussion among stakeholders on the future priorities of the PID community. All participants were actively engaged in the entire Summit, bringing provocative questions to ensure a high level of discussion and engagement, and partnered in identifying the outlooks, unmet needs, hurdles and opportunities of PIDs for 2030. The topics that were covered include diagnosis (e.g., newborn screening [NBS], genomic sequencing\u2014 including ethical aspects on the application of genomics on NBS, the role of more accurate and timely diagnostics in impacting personalized management), treatment (e.g., the therapeutic evolution of immunoglobulins in a global environment, new therapies such as targeted therapies, new approaches in curative therapies), the interactions of Primary ID with Secondary ID, Autoinflammatory Diseases and other diseases as the field experiences an incessant evolution, and also the avenues for research in the field of humanities and human sciences such as Patient-Reported Outcome Measures (PROMs), Patient-Reported Experience Measures (PREMs), and Health-Related Quality Of Life (HRQoL). During this meeting, all participants contributed to the drafting of recommendations based on our common understanding of the future opportunities, challenges, and scenarios. As a collection of materials, perspectives and summaries, they are succinct and impactful and may help determine some of the next key steps for the PID community.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1245718","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T23:09:01Z","timestamp":1692227341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities \u2014 proceedings from the IPOPI global multi-stakeholders\u2019 summit (June 2022)"],"prefix":"10.3389","volume":"14","author":[{"given":"Susan","family":"Tadros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Pr\u00e9vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"S\u00e1nchez-Ram\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla H.","family":"Erwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hotchko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Drabwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samya","family":"Van Coillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Pergent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan O.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Mahlaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00627","article-title":"Primary immune deficiencies - principles of care","volume":"5","author":"Chapel","year":"2014","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780140","article-title":"The PID principles of care: where are we now? A global status report based on the PID life index","volume":"12","author":"Nordin","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"722\u22128","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1\u221246","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B5","volume-title":"Commissioning Criteria Policy for the use of therapeutic immunoglobulin (Ig) England, 2021","year":"2021"},{"key":"B6","volume-title":"National Immunoglobulin Database Report 2019\/20","author":"Foster","year":"2021"},{"key":"B7","unstructured":"Ig usage data and statistics2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"426\u221231","DOI":"10.2500\/aap.2016.37.3987","article-title":"Intravenous and subcutaneous immunoglobulin G replacement therapy","volume":"37","author":"Bonilla","year":"2016","journal-title":"Allergy Asthma Proc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S31136","article-title":"Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency","volume":"2","author":"Jolles","year":"2013","journal-title":"ImmunoTargets Ther"},{"key":"B10","volume-title":"Plasma Flows On A Global Level \u2013 Why It Travels So Far","author":"Hotchko","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","volume-title":"An EU-wide overview of the market of blood, blood components and plasma derivatives focusing on their availability for patients","year":"2016"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"666\u221279","DOI":"10.1007\/s10875-021-00980-1","article-title":"The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee","volume":"41","author":"Tangye","year":"2021","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"212\u221225","DOI":"10.1007\/s12016-021-08838-5","article-title":"Next-generation sequencing in the field of primary immunodeficiencies: current yield, challenges, and future perspectives","volume":"61","author":"Vorsteveld","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"740\u22124","DOI":"10.1038\/s41431-018-0114-6","article-title":"Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing","volume":"26","author":"Costain","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2137\u221249","DOI":"10.1084\/jem.20140520","article-title":"Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies","volume":"211","author":"Casanova","year":"2014","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"377\u221287","DOI":"10.1016\/S2213-2600(15)00139-3","article-title":"Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings","volume":"3","author":"Willig","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56\u221266","DOI":"10.1007\/s10875-017-0455-x","article-title":"Newborn screening for primary immunodeficiency diseases: history, current and future practice","volume":"38","author":"King","year":"2018","journal-title":"J Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e843","DOI":"10.1002\/ctm2.843","article-title":"A pilot study of assessing whole genome sequencing in newborn screening in unselected children in China","volume":"12","author":"Jian","year":"2022","journal-title":"Clin Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02987","article-title":"Newborn screening for primary immunodeficiencies: the gaps, challenges, and outlook for developing countries","volume":"42","author":"El-Sayed","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns8020031","article-title":"Towards achieving equity and innovation in newborn screening across Europe","volume":"8","author":"Sikonja","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.lanepe.2022.100311","article-title":"Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe","volume":"13","author":"Scarpa","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717388","article-title":"Emerging place of JAK inhibitors in the treatment of inborn errors of immunity","volume":"12","author":"Hadjadj","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"327\u221230","DOI":"10.1016\/j.jaci.2015.08.036","article-title":"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4","volume":"137","author":"Lee","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"761\u221273","DOI":"10.1016\/j.jaip.2018.12.017","article-title":"Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases","volume":"7","author":"Leiding","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101\u221212","DOI":"10.1159\/000503997","article-title":"Targeted therapy with biologicals and small molecules in primary immunodeficiencies","volume":"29","author":"Delmonte","year":"2020","journal-title":"Med Princ Pract Int J Kuwait Univ Health Sci Cent"},{"key":"B29","doi-asserted-by":"publisher","first-page":"917\u221231","DOI":"10.1182\/blood-2017-09-807487","article-title":"Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency","volume":"131","author":"Fox","year":"2018","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1230\u221243","DOI":"10.1007\/s10875-022-01278-6","article-title":"Retrospective, landmark analysis of long-term adult morbidity following allogeneic HSCT for inborn errors of immunity in infancy and childhood","volume":"42","author":"Day","year":"2022","journal-title":"J Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1666\u221276","DOI":"10.1182\/blood.2020008187","article-title":"How I use allogeneic HSCT for adults with inborn errors of immunity","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1097\/HS9.0000000000000509","article-title":"Gene therapy for primary immunodeficiency","volume":"5","author":"Houghton","year":"2021","journal-title":"HemaSphere"},{"key":"B33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jpeds.2017.10.029","article-title":"Burden of poor health conditions and quality of life in 656 children with primary immunodeficiency","volume":"194","author":"Barlogis","year":"2018","journal-title":"J Pediatr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jaci.2016.08.027","article-title":"Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study","volume":"139","author":"Barlogis","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"602\u22129","DOI":"10.1007\/s10875-020-00775-w","article-title":"Health-related quality of life and multidimensional fatigue scale in children with primary immunodeficiencies","volume":"40","author":"Ridao-Manonellas","year":"2020","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"621\u22129","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"B37","doi-asserted-by":"publisher","first-page":"603\u221210","DOI":"10.3349\/ymj.2012.53.3.603","article-title":"Health related quality of life in common variable immunodeficiency","volume":"53","author":"Quinti","year":"2012","journal-title":"Yonsei Med J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S3\u221211","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1179\u221294","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"89\u2212102","DOI":"10.1016\/j.jclinepi.2015.08.038","article-title":"PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions","volume":"73","author":"Cook","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"379\u221288","DOI":"10.1007\/s12026-020-09162-4","article-title":"PROMIS-29 survey confirms major impact of fatigue on health-related quality of life in common variable immunodeficiency","volume":"68","author":"Zhang","year":"2020","journal-title":"Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"461\u221275","DOI":"10.1007\/s10875-017-0404-8","article-title":"Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment","volume":"37","author":"Rider","year":"2017","journal-title":"J Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1451\u221260","DOI":"10.1007\/s10875-022-01286-6","article-title":"Quality of life and social and psychological outcomes in adulthood following allogeneic HSCT in childhood for inborn errors of immunity","volume":"42","author":"Nicholson","year":"2022","journal-title":"J Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2116\u221225","DOI":"10.1016\/j.jaci.2021.12.790","article-title":"An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years","volume":"149","author":"Alligon","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1245718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T23:09:07Z","timestamp":1692227347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1245718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2023.1245718"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1245718","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"article-number":"1245718"}}